MENU

Efficient Implementation of DPYD Testing Using an Institutional Genetics Data Repository

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Professor, University of Michigan College of Pharmacy
    Biography

      Dr. Hertz is an assistant professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy. Dr. Hertz received his PharmD from Rutgers University and PhD from UNC for his dissertation research on pharmacogenetic predictors of taxane-induced neuropathy. Dr. Hertz’s current research is interested in developing tools for individualizing treatment in patients with cancer and translating them into clinical practice. He has a particular interest in optimal use of paclitaxel for women with breast cancer, including identification of an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity. Dr. Hertz has several other ongoing projects to discover and translate genetic variants that affect cancer treatment outcomes, in collaborations with medical oncologists at the University of Michigan Rogel Cancer Center and within SWOG.


    Abstract

    5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity genetic variants in DPYD, which encodes the enzyme that metabolizes fluoropyrimidine, leading to higher systemic drug exposure and increased risk of severe and fatal toxicity. Many European countries recommend DPD/DPYD screening prior to fluoropyrimidine treatment and there are guidelines from Clinical Pharmacogenetics Implementation Consortium (CPIC) that recommend safe fluoropyrimidine starting doses in known DPYD carriers. However, DPYD testing is not recommended by the FDA or clinical oncology practice guidelines, which has led to minimal testing in the United States. One of the main reasons for the lack of clinical uptake is the cost of testing large numbers of patients to find the relatively uncommon (~5%) DPYD carriers. A potential solution that has not been explored, to our knowledge, is to use existing research-only genetic data to identify suspected carriers of actionable genotypes who should undergo confirmatory testing prior to treatment. This talk will summarize the evidence of the clinical benefit of pre-treatment DPYD testing and the reasons that testing is rarely conducted in the US. I will then describe ongoing work to use an institutional genetic data repository for ultra-efficient DPYD implementation at the University of Michigan Rogel Cancer Center. Finally, I will describe our efforts to get oncology clinical guidelines and the FDA to recommend pre-treatment DPYD testing and give the audience a simple way to support our effort. 

    Learning Objectives:

    1. Identify the five actionable DPYD variants that increase risk of fluoropyrimidine toxicity

    2. Describe the main reasons that pre-treatment DPYD testing is not conducted in the United States

    3. Recognize the benefits of using existing institutional genetic data for efficient pharmacogenetic implementation


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds
    Attendees
    • See more